Insight Molecular Diagnostics (IMDX) Accounts Payables (2020 - 2025)
Historic Accounts Payables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.1 million.
- Insight Molecular Diagnostics' Accounts Payables rose 720.81% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 720.81%. This contributed to the annual value of $2.3 million for FY2024, which is 13913.96% up from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Accounts Payables is $1.1 million, which was up 720.81% from $1.3 million recorded in Q2 2025.
- Insight Molecular Diagnostics' 5-year Accounts Payables high stood at $5.3 million for Q1 2021, and its period low was $908000.0 during Q1 2024.
- In the last 5 years, Insight Molecular Diagnostics' Accounts Payables had a median value of $1.9 million in 2021 and averaged $2.0 million.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Accounts Payables crashed by 7017.59% in 2023, and later skyrocketed by 15099.12% in 2025.
- Over the past 5 years, Insight Molecular Diagnostics' Accounts Payables (Quarter) stood at $2.1 million in 2021, then fell by 12.85% to $1.8 million in 2022, then plummeted by 47.55% to $953000.0 in 2023, then soared by 139.14% to $2.3 million in 2024, then crashed by 53.66% to $1.1 million in 2025.
- Its Accounts Payables stands at $1.1 million for Q3 2025, versus $1.3 million for Q2 2025 and $2.3 million for Q1 2025.